Abstract Hiroki Teragawa¹, Kenji Nishioka¹, Yukihito Higashi², Kazuaki Chayama³ and Yasuki Kihara¹

¹Department of Cardiovascular Medicine, ²Department of Cardiovascular Physiology and Medicine, and ³Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 734-8551, Japan.

Abstract

Coronary spasm plays an important role in the pathogenesis of variant angina as well as ischaemic heart diseases. Treatment with vasodilators such as long-acting calcium channel blockers and long-acting nitrates is generally effective in preventing coronary spasm; however, in some patients coronary spasm is refractory to standard therapy. Because of endothelial dysfunction, hyper-reactivity of coronary smooth muscle cells and other triggering factors involved in the pathogenesis of coronary spasm, drugs capable of improving these conditions may be effective in preventing medically refractory coronary spasm. In addition, a spasm provocation test is frequently performed when diagnosing coronary spasms. Although intracoronary administration of nitroglycerin generally relieves the coronary spasm that results from this test, we have encountered patients who suffered haemodynamic instability during the test. Drugs that stabilize haemodynamics and dilate the coronary artery are effective in such situations. We review treatment options for coronary spasm that are refractory to the standard oral medications and to intracoronary infusion of nitroglycerin during the spasm provocation test.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN